BT1769

BT1769 is an investigational **MT1-MMP-targeted Bicycle toxin conjugate** being developed by **Bicycle Therapeutics** for **osteosarcoma**. It is a **peptide-drug conjugate** built on the company's Bicycle platform and comprises a synthetic **bicyclic targeting peptide** that binds **membrane type 1 matrix metalloproteinase** with high affinity, linked through an **enzymatically cleavable dipeptide linker** to the microtubule-disrupting payload **monomethyl auristatin E**. In preclinical osteosarcoma models, BT1769 showed encouraging antitumor activity, including objective responses in patient-derived xenograft models, supporting its use as a targeted cytotoxic therapy for MT1-MMP-expressing tumors.

Other names

MT1-MMP-targeted Bicycle toxin conjugateMT-1-MMP-targeted Bicycle toxin conjugateMT 1-MMP-targeted Bicycle toxin conjugate